Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 12, 2003

View Archived Issues

NaPro receives SBIR grant for work in Duchenne muscular dystrophy

Vion enters research and option agreement for novel anticancer compounds

Disease stabilization in phase II multiple myeloma study of Panzem

Human challenge study of FluINsure confirms efficacy of vaccine

Safety and clinical efficacy of GW-572016 in advanced breast cancer

BMS-247550 in metastatic breast cancer

Palifermin improves quality of life in cancer patients with oral mucositis

New PARP inhibitors described by KuDOS and Maybridge scientists

GSK patent covers novel p38 MAP kinase inhibitors and their use

Schering AG researchers claim new PLK inhibitors for cancer and other uses

New opioid receptors modulators prepared and tested at Janssen

Merck KGaA claims novel semicarbazide-based factor Xa and/or factor VIIa inhibitors

Series of mGluR antagonists described by Euroceltique researchers in a recent patent

SC-12267 advanced into phase I for rheumatoid arthritis

Celmed BioSciences and NIH to test Theralux for GvHD

Grant supports matriptase inhibitor development at Curacyte

New preclinical and phase I data presented for CYC-202

Genta completes NDA submission for Genasense for malignant melanoma

Continued positive interim data from phase II extension study of Alzhemed

Immediate-release indiplon shows promise for MOTN administration

Bayer acquires Fosrenol rights in Japan

Belgian phase I trial evaluates tgAAC09

TGN-255 shows desired anticoagulant pharmacodynamic properties in phase I study

ICL-670 in beta-thalassemia and associated transfusional iron overload

Safety profile of sustained-release bupropion in epilepsy patients

Clinical benefits of pregabalin in epilepsy

Antiangiogenic PKC-beta inhibitor identified at J&J

Nonhypercalcemic vitamin D3 analogue HY-11 shows promising antileukemic activity

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...